Cardene I.V. (nicardipine hydrochloride) Premixed Injection
Indication
Cardene I.V. (nicardipine hydrochloride) Premixed Injection is a calcium channel blocker indicated for the short-term treatment of hypertension when oral therapy is not feasible or not desirable. For prolonged control of blood pressure, transfer patients to oral medication as soon as their clinical condition permits. Please read the accompanying full Indication(s) and Important Risk Information and full Prescribing Information.
Rapid Acting 2 and Titrated 1
Cardene I.V. can be stored at the point of care at room temperature of 68-77oF (20-25oC) in its original carton and protected from light until its administration.1 Cardene I.V. (nicardipine HCl) acts rapidly2 and blood pressure begins to fall within minutes, and the formulation allows for rapid (q 5 min) or gradual (q 15 min) titration.1
Manufacturer-prepared premixed
Ready to administer bags
Two-year shelf life at room temperature
Can be stored at point of care
Store in carton to protect from light until ready to use
An antihypertensive agent that fits your patients’ needs
Cardene I.V. has documented efficacy in different clinical settings in treating patients with acute severe hypertension or acute postoperative hypertension.1
Selected Important Risk Information
● Cardene I.V. is contraindicated in patients with advanced aortic stenosis.
● If unacceptable hypotension or tachycardia occurs, discontinue the CARDENE I.V. Infusion. When blood pressure and heart rate stabilize, restart the infusion at low doses.
Please read the accompanying full Indication(s) and Important Risk Information and full Prescribing Information.
Explore Our Related Products
INDICATION AND IMPORTANT RISK INFORMATION FOR CARDENE I.V.
Indication
CARDENE I.V. (nicardipine hydrochloride) Premixed Injection is a calcium channel blocker indicated for the short-term treatment of hypertension when oral therapy is not feasible or not desirable. For prolonged control of blood pressure, transfer patients to oral medication as soon as their clinical condition permits.
Important Risk Information
Contraindications
Do not use in patients with advanced aortic stenosis.
Warnings and precautions
- If unacceptable hypotension or tachycardia occurs, discontinue the CARDENE I.V. Infusion. When blood pressure and heart rate stabilize, restart the infusion at low doses.
- Titrate slowly when using CARDENE I.V., particularly in combination with a beta-blocker, in patients with heart failure or significant left ventricular dysfunction because of possible negative inotropic effects.
- Closely monitor response to CARDENE I.V. in patients with angina, heart failure, impaired hepatic function, or renal impairment.
- To reduce the possibility of venous thrombosis, phlebitis, local irritation, swelling, extravasation, and the occurrence of vascular impairment, administer drug through large peripheral veins or central veins rather than arteries or small peripheral veins. To minimize the risk of peripheral venous irritation, change the site of infusion of CARDENE I.V. every 12 hours.
- The most common adverse reactions are headache (15%), hypotension (6%), tachycardia (4%), and nausea/vomiting (5%).
- Cimetidine increases oral nicardipine plasma levels.
- CARDENE I.V. may increase cyclosporine and tacrolimus plasma levels. Frequent monitoring of trough blood levels is recommended when co-administering CARDENE I.V.
- Pregnancy: Based on animal data may cause fetal harm. CARDENE I.V. should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Dosage and Administration
- Inspect CARDENE I.V. visually for particulate matter and discoloration prior to administration. CARDENE I.V. is normally a clear, colorless to yellow solution.
- Do not combine CARDENE I.V. with any product in the same intravenous line or premixed container. Do not add supplementary medication to the bag. Protect from light until ready to use.
Please click here for full prescribing information